Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBV-AST Cell Infusion for EBV-DNA Viremia Post Allo-HSCT
NCT07438067Phase 1Recruiting
- Sponsor
- Daihong Liu
- Start
- Mar 2025
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in Epstein-Barr virus infection, sponsored by Daihong Liu. Primary endpoint: Maximum Tolerated Dose of EBV-AST Cell Infusion. Started Mar 2025; status: recruiting.
02
Conditions
Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT07438067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07438067.